Interferon and ribavirin therapy for chronic hepatitis C virus genotype 6: A comparison with genotype 1

Journal of Infectious Diseases

Volumn 187, Issue 7, 2003, Pages 1071-1074

  Hui, Chee Kin ^a   Yuen, Man Fung ^a   Sablon, Erwin ^b   Chan, Annie On On ^a   Wong, Benjamin Chun Yu ^a   Lai, Ching Lung ^a,c  

^a UNIVERSITY OF HONG KONG   (Hong Kong)

^b INNOGENETICS   (Belgium)

^c QUEEN MARY HOSPITAL   (Hong Kong)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASE; RECOMBINANT ALPHA2B INTERFERON; RIBAVIRIN; VIRUS RNA;

ADULT; AGED; ANTIVIRAL ACTIVITY; ARTICLE; CHRONIC HEPATITIS; CLINICAL ARTICLE; CLINICAL TRIAL; DOSE TIME EFFECT RELATION; DRUG SPECIFICITY; ENZYME ASSAY; FEMALE; GENETIC ASSOCIATION; GENOTYPE; HEPATITIS C VIRUS; HEPATITIS C VIRUS GENOTYPE 1; HEPATITIS C VIRUS GENOTYPE 6; HUMAN; IMMUNE RESPONSE; INTERMETHOD COMPARISON; MALE; NONHUMAN; PRIORITY JOURNAL; PROSPECTIVE STUDY; SERODIAGNOSIS; STATISTICAL SIGNIFICANCE; SUSTAINED VIROLOGICAL RESPONSE; TREATMENT OUTCOME; VIRUS DETECTION; VIRUS TYPING;

ADULT; AGED; AGED, 80 AND OVER; ANTIVIRAL AGENTS; DRUG THERAPY, COMBINATION; FEMALE; GENES, VIRAL; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INTERFERON ALFA-2B; MALE; MIDDLE AGED; RIBAVIRIN;

EID: 0037385492     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/368217     Document Type: Article

References (15)

1. National Institutes of Health Consensus Development Conference panel statement: management of hepatitis C. Hepatology 1997; 26:2S-10S.
2. Okomoto H, Mishiro S. Genetic heterogeneity of hepatitis C virus. Intervirology 1994;37:68-76.
3. McOmish F, Yap PL, Dow BC, et al. Geographical distribution of hepatitis C virus genotypes in blood donors: an international collaborative survey. J Clin Microbiol 1994; 32:884-92.
4. Davidson F, Simmonds P, Ferguson JC, et al. Survey of major genotypes and subtypes of hepatitis C virus using RFLP of sequences amplified from the 5′ non-coding region. J Gen Virol 1995; 76:1197-204.
5. Mellor J, Walsh EA, Prescott LE, et al. Survey of type 6 group variants of hepatitis C virus in southeast Asia by using a core based genotyping assay. J Clin Microbiol 1996; 34:417-23.
6. McHutchison JG, Gordon SC, Schiff ER, et al. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. N Engl J Med 1998; 339:1485-92.
7. Poypard T, Marcellin P, Lee SS, et al. Randomized trial of interferon α2b plus ribavirin for 48 weeks or for 24 weeks versus interferon α2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. Lancet 1998; 352:1426-32.
8. Stuyver L, Wyseur A, Van Arnhem W, Hernandez F, Maertens G. Second-generation line probe assay for hepatitis C genotypes. J Clin Microbiol 1996; 34:2259-66.
9. Dev AT, McCaw R, Sundararajan V, Bowden S, Sievert W. Southeast Asian patients with chronic hepatitis C: the impact of novel genotypes and race on treatment outcome. Hepatology 2002; 36:1259-65.
10. Desmet VJ, Gerber M, Hoofnagle JH, Manns M, Scheuer PJ. Classification of chronic hepatitis: diagnosis, grading and staging. Hepatology 1994; 19:1513-20.
11. Al-Faleh FZ, Aljumah A, Rezeig M, et al. Treatment of chronic hepatitis C genotype IV with interferon-ribavirin combination in Saudi Arabia: a multicentre study. J Viral Hepat 2000; 7:287-91.
12. Prescott LE, Simmonds P, Lai CL, et al. Detection and clinical features of hepatitis C virus type 6 infections in blood donors from Hong Kong. J Med Virol 1996; 50:168-75.
13. Wong DA, Tong LK, Lim W. High prevalence of hepatitis C genotype 6 among certain risk groups in Hong Kong. Eur J Epidemiol 1998; 14:421-6.
14. Fried MW, Schiffman M, Sterling RK, et al. A multicenter, randomized trial of daily high-dose interferon-alfa 2b for the treatment of chronic hepatitis C: pretreatment stratification by viral burden and genotype. Am J Gastroenterol 2000; 95:3225-9.
15. McHutchison JG, Poynard T, Pianko S, et al. The impact of interferon and ribavirln on response to therapy in black patients with chronic hepatitis C. Gastroenterology 2000; 119:1317-23.